Moderna Redesigns Its Covid Vaccine to Produce Stronger Immunity Against Omicron
Moderna on Tuesday released clinical data demonstrating that a new version of its Covid-19 vaccine that targets several mutations produced a stronger immune response against the major virus variants, including omicron and delta, than the company’s current shots.
The biotech company’s redesigned vaccine targets nine mutations found in the beta Covid variant, as well as the original strain of the virus that first emerged in Wuhan, China, in late 2019. Four of the mutations targeted by the updated vaccine are shared with omicron. Moderna and Pfizer are developing new shots that target multiple virus variants in the hope of producing vaccines that provide longer-lasting protection against infection.